Literature DB >> 18312037

A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.

Michael R Law1, Stephen B Soumerai, Dennis Ross-Degnan, Alyce S Adams.   

Abstract

OBJECTIVE: Previous cross-sectional studies have suggested an association between medication nonadherence and hospitalization for individuals with schizophrenia. However, such analyses typically measure adherence averaged over long time periods. We investigated the temporal relationship between nonadherence and hospitalization risk using a daily measure of medication availability.
METHOD: Our observational cohort included 1191 patients with schizophrenia (ICD-9 criteria) enrolled in Maine and New Hampshire Medicaid programs who initiated atypical antipsychotic therapy between January 1, 2001, and December 31, 2003. Pharmacy claims were used to define days with gaps in medication availability. We tested the association of gaps in medication availability with all-cause, mental health, and schizophrenia-specific hospitalization using a Cox regression model.
RESULTS: Compared to individuals with available medication, individuals in the first 10 days following a missed prescription refill had a hazard ratio of 1.54 (95% CI = 1.02 to 2.32) for mental health hospitalization and 1.77 (95% CI = 1.16 to 2.71) for schizophrenia hospitalization. Similarly, medication gaps of more than 30 days were associated with 50% increased hazard for all 3 hospitalization outcomes. Switching and augmenting therapy, previous hospitalization, and clinical severity measures were also associated with substantially increased hazard of hospitalization.
CONCLUSION: Our findings indicate that patients may be at significantly increased risk for hospitalization as early as the first 10 days following a missed medication refill. Patients who switched or augmented medications or were previously hospitalized also demonstrated increased hospitalization risk. Clinicians and Medicaid programs should consider using pharmacy claims to monitor medication use and target adherence interventions to reduce relapses in this vulnerable population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312037     DOI: 10.4088/jcp.v69n0107

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  49 in total

Review 1.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

2.  Ethical considerations when treating patients with schizophrenia.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2008-04

3.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

4.  Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).

Authors:  Ulrike Stentzel; Neeltje van den Berg; Lara N Schulze; Thea Schwaneberg; Franziska Radicke; Jens M Langosch; Harald J Freyberger; Wolfgang Hoffmann; Hans-Jörgen Grabe
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

5.  Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.

Authors:  Julie Kreyenbuhl; Eric P Slade; Deborah R Medoff; Clayton H Brown; Benjamin Ehrenreich; Joseph Afful; Lisa B Dixon
Journal:  Schizophr Res       Date:  2011-05-14       Impact factor: 4.939

6.  Adjuvant chemotherapy for breast cancer in patients with schizophrenia.

Authors:  Mark Hwang; Mishel Farasatpour; Campbell D Williams; Julie A Margenthaler; Katherine S Virgo; Frank E Johnson
Journal:  Oncol Lett       Date:  2012-01-09       Impact factor: 2.967

7.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

8.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

9.  Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.

Authors:  Haya Ascher-Svanum; Xiaomei Peng; Douglas Faries; William Montgomery; Peter M Haddad
Journal:  BMC Psychiatry       Date:  2009-07-29       Impact factor: 3.630

10.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; David Salkever; Eric P Slade; Xiaomei Peng; Robert R Conley
Journal:  BMC Psychiatry       Date:  2010-01-07       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.